Related Experiment Video
Updated: Aug 11, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Medical oncology]
1IMO, Clinique de Genolier, 1272 Genolier. maapro@genolier.net
Abstract:
Patients are more and more often coming to see the physician with reprints from the Oracle of modem times, (the Internet). Facing the rapid development of new anticancer drugs, even the expert can have difficulties in knowing which ones have already rigorous comparative trials and which results are really clinically significant, leading to important improvements in the treatment of patients with solid tumors. In past years we had already noticed that in some cancer types, these progresses unfortunately sometimes remain of marginal importance. Survival benefits are not always well established and, confronted with the exploding costs of medicine, the physician may not always want to use some promising drugs. This review summarizes results of some of the most important randomized clinical trials, but does not attempt to solve the cost-benefit question.
Insights
This review examines randomized clinical trials for new anticancer drugs, highlighting challenges in assessing clinical significance and patient benefit for solid tumors. It clarifies which treatments offer marginal versus substantial improvements, aiding physician decision-making.
Area of Science:
- Oncology
- Clinical Pharmacology
Context:
- Increasing patient access to online medical information necessitates clear interpretation of new anticancer drug trial data.
- Experts face challenges in differentiating clinically significant advancements from marginal improvements in cancer therapeutics.
- The high cost of novel cancer drugs complicates treatment decisions, especially when survival benefits are not definitively established.
Purpose:
- To review key randomized clinical trials for novel anticancer agents targeting solid tumors.
- To assess the clinical significance and patient impact of recent advancements in cancer drug development.
- To provide physicians with a clearer understanding of evidence-based treatment options.
Summary:
- Summarizes results from major randomized clinical trials of new anticancer drugs for solid tumors.
- Evaluates the real-world clinical significance and patient survival benefits derived from these trials.
- Highlights instances where treatment advancements offer only marginal improvements.
Impact:
- Aids oncologists in navigating the complex landscape of new cancer drug approvals and trial data.
- Supports evidence-based clinical decision-making for solid tumor treatment.
- Provides a foundation for understanding the value of novel cancer therapies beyond initial trial results.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers